Lotte Lips1, Camiel L M de Roij van Zuijdewijn1,2, Piet M Ter Wee1,2, Michiel L Bots3, Peter J Blankestijn4, Marinus A van den Dorpel5, Denis Fouque6, Renate de Jongh7, Solenne Pelletier6, Marc G Vervloet1,2, Menso J Nubé1,2, Muriel P C Grooteman1,2. 1. Department of Nephrology, VU University Medical Center, Amsterdam, The Netherlands. 2. Institute for Cardiovascular Research VU University Medical Center (ICaR-VU), VU University Medical Center, Amsterdam, The Netherlands. 3. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. 4. Department of Nephrology, University Medical Center Utrecht, Utrecht, The Netherlands. 5. Department of Internal Medicine, Maasstad Hospital, Rotterdam, The Netherlands. 6. Centre Hospitalier Universitaire de Lyon, Pierre Benite, France. 7. Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.
Abstract
BACKGROUND: The glycoprotein sclerostin (Scl; 22 kDa), which is involved in bone metabolism, may play a role in vascular calcification in haemodialysis (HD) patients. In the present study, we investigated the relation between serum Scl (sScl) and mortality. The effects of dialysis modality and the magnitude of the convection volume in haemodiafiltration (HDF) on sScl were also investigated. METHODS: In a subset of patients from the CONTRAST study, a randomized controlled trial comparing HDF with HD, sScl was measured at baseline and at intervals of 6, 12, 24 and 36 months. Patients were divided into quartiles, according to their baseline sScl. The relation between time-varying sScl and mortality with a 4-year follow-up period was investigated using crude and adjusted Cox regression models. Linear mixed models were used for longitudinal measurements of sScl. RESULTS: The mean (±standard deviation) age of 396 test subjects was 63.6 (±13.9 years), 61.6% were male and the median follow-up was 2.9 years. Subjects with the highest sScl had a lower mortality risk than those with the lowest concentrations [adjusted hazard ratio 0.51 (95% confidence interval, CI, 0.31-0.86, P = 0.01)]. Stratified models showed a stable sScl in patients treated with HD (Δ +2.9 pmol/L/year, 95% CI -0.5 to +6.3, P = 0.09) and a decreasing concentration in those treated with HDF (Δ -4.5 pmol/L/year, 95% CI -8.0 to -0.9, P = 0.02). The relative change in the latter group was related to the magnitude of the convection volume. CONCLUSIONS: (i) A high sScl is associated with a lower mortality risk in patients with end-stage kidney disease; (ii) treatment with HDF causes sScl to fall; and (iii) the relative decline in patients treated with HDF is dependent on the magnitude of the convection volume.
BACKGROUND: The glycoprotein sclerostin (Scl; 22 kDa), which is involved in bone metabolism, may play a role in vascular calcification in haemodialysis (HD) patients. In the present study, we investigated the relation between serum Scl (sScl) and mortality. The effects of dialysis modality and the magnitude of the convection volume in haemodiafiltration (HDF) on sScl were also investigated. METHODS: In a subset of patients from the CONTRAST study, a randomized controlled trial comparing HDF with HD, sScl was measured at baseline and at intervals of 6, 12, 24 and 36 months. Patients were divided into quartiles, according to their baseline sScl. The relation between time-varying sScl and mortality with a 4-year follow-up period was investigated using crude and adjusted Cox regression models. Linear mixed models were used for longitudinal measurements of sScl. RESULTS: The mean (±standard deviation) age of 396 test subjects was 63.6 (±13.9 years), 61.6% were male and the median follow-up was 2.9 years. Subjects with the highest sScl had a lower mortality risk than those with the lowest concentrations [adjusted hazard ratio 0.51 (95% confidence interval, CI, 0.31-0.86, P = 0.01)]. Stratified models showed a stable sScl in patients treated with HD (Δ +2.9 pmol/L/year, 95% CI -0.5 to +6.3, P = 0.09) and a decreasing concentration in those treated with HDF (Δ -4.5 pmol/L/year, 95% CI -8.0 to -0.9, P = 0.02). The relative change in the latter group was related to the magnitude of the convection volume. CONCLUSIONS: (i) A high sScl is associated with a lower mortality risk in patients with end-stage kidney disease; (ii) treatment with HDF causes sScl to fall; and (iii) the relative decline in patients treated with HDF is dependent on the magnitude of the convection volume.
Authors: Cristina Novo-Rodríguez; Beatriz García-Fontana; Juan De Dios Luna-Del Castillo; Francisco Andújar-Vera; Verónica Ávila-Rubio; Cristina García-Fontana; Sonia Morales-Santana; Pedro Rozas-Moreno; Manuel Muñoz-Torres Journal: PLoS One Date: 2018-06-21 Impact factor: 3.240
Authors: Annelies De Maré; Stuart Maudsley; Abdelkrim Azmi; Jhana O Hendrickx; Britt Opdebeeck; Ellen Neven; Patrick C D'Haese; Anja Verhulst Journal: Toxins (Basel) Date: 2019-07-21 Impact factor: 4.546
Authors: Annelies De Maré; Britt Opdebeeck; Ellen Neven; Patrick C D'Haese; Anja Verhulst Journal: J Bone Miner Res Date: 2022-02-15 Impact factor: 6.390